Telix Pharmaceuticals Limited (ASX: TLX)

Telix Pharmaceuticals Cash Flow Statement

Financials in millions AUD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	5.21	-104.08	-80.51	-44.89	-27.87
Depreciation & Amortization	6.92	5.38	5.17	4.88	4.24
Share-Based Compensation	8.79	8.11	1.32	2.35	1.27
Other Operating Activities	2.96	26.62	14.69	39.62	-0.97
Operating Cash Flow	23.88	-63.97	-59.33	1.96	-23.33
Capital Expenditures	-10.79	-13.86	-1.34	-0.32	-0.47
Acquisitions	0	-0.97	0	-0.32	0
Change in Investments	-13.16	-	-	-	-
Other Investing Activities	-1.54	-2.16	-1.39	-0.45	-
Investing Cash Flow	-25.49	-17	-2.73	-1.09	-0.47
Common Stock Issued	6.65	173.22	3.78	35.02	43.89
Share Repurchases	0	-7.82	0	-0.13	0
Other Financing Activities	3.53	-6.08	-0.94	-1.03	-1.17
Financing Cash Flow	10.19	174.96	2.85	34.12	42.72
Net Cash Flow	6.91	94.29	-55.91	33.35	18.83
Free Cash Flow	13.09	-77.83	-60.67	1.64	-23.8
Free Cash Flow Margin	2.64%	-48.62%	-798.67%	31.42%	-682.96%
Free Cash Flow Per Share	0.04	-0.25	-0.21	0.01	-0.10

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.